Supernus Pharma (SUPN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Supernus Announces First Quarter 2023 Financial Results
May 9, 2023 4:05 PM EDTFirst quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022GOCOVRI® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022Excluding net product sales of Trokendi XR® in both periods, total net product sales increased 25% First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0... More
